Literature DB >> 1560376

Effects of buprenorphine and other opioid agonists and antagonists on alfentanil- and cocaine-reinforced responding in rhesus monkeys.

G Winger1, P Skjoldager, J H Woods.   

Abstract

Rhesus monkeys self-administered a range of doses of either cocaine or alfentanil under a fixed-ratio 30, time out 45 sec schedule of i.v. drug delivery. Buprenorphine suppressed responding maintained by both cocaine and alfentanil; however, much larger doses of buprenorphine were required to suppress cocaine-reinforced as opposed to alfentanil-reinforced responding. Neither cocaine nor alfentanil dose-effect curves were shifted to the right by buprenorphine, but were simply shifted downward. Opioid agonists heroin and nalbuphine produced similar downward shifts in both alfentanil and cocaine dose-effect curves; unlike buprenorphine, similar doses of heroin and nalbuphine suppressed behavior maintained by both cocaine and alfentanil. Increasing doses of the pure opioid antagonist quadazocine produced shifts to the right in the alfentanil rate-maintaining dose-effect curves but had no dose-related effect on behavior maintained by cocaine. The data suggest that buprenorphine suppresses drug-maintained responding through an agonist action but that alfentanil-maintained responding is uniquely sensitive to buprenorphine's effects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560376

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  HS014, a selective melanocortin-4 (MC4) receptor antagonist, modulates the behavioral effects of morphine in mice.

Authors:  N Eser Ercil; Ruggero Galici; Robert A Kesterson
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

2.  Combined effects of buprenorphine and a nondrug alternative reinforcer on i.v. cocaine self-administration in rats maintained under FR schedules.

Authors:  S D Comer; S T Lac; C L Wyvell; M E Carroll
Journal:  Psychopharmacology (Berl)       Date:  1996-06       Impact factor: 4.530

3.  Enhancement of cocaine's abuse liability in methadone maintenance patients.

Authors:  K L Preston; J T Sullivan; E C Strain; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

4.  The opioid receptor triple agonist DPI-125 produces analgesia with less respiratory depression and reduced abuse liability.

Authors:  Shou-Pu Yi; Qing-Hong Kong; Yu-Lei Li; Chen-Ling Pan; Jie Yu; Ben-Qiang Cui; Ying-Fei Wang; Guan-Lin Wang; Pei-Lan Zhou; Li-Li Wang; Ze-Hui Gong; Rui-Bin Su; Yue-Hai Shen; Gang Yu; Kwen-Jen Chang
Journal:  Acta Pharmacol Sin       Date:  2017-05-15       Impact factor: 6.150

5.  The effects of amphetamine, butorphanol, and their combination on cocaine self-administration.

Authors:  Mark A Smith; Michael M Pennock; Elizabeth G Pitts; Katherine L Walker; Kimberly C Lang
Journal:  Behav Brain Res       Date:  2014-08-12       Impact factor: 3.332

6.  Abuse liability of mitragynine assessed with a self-administration procedure in rats.

Authors:  Kai Yue; Theresa A Kopajtic; Jonathan L Katz
Journal:  Psychopharmacology (Berl)       Date:  2018-07-23       Impact factor: 4.530

7.  Self administration of cocaine in monkeys receiving LAAM acutely or chronically.

Authors:  Lisa R Gerak; Ruggero Galici; Charles P France
Journal:  Physiol Behav       Date:  2007-07-28

Review 8.  Controversies in translational research: drug self-administration.

Authors:  Margaret Haney; Roger Spealman
Journal:  Psychopharmacology (Berl)       Date:  2008-02-19       Impact factor: 4.530

9.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

10.  Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.

Authors:  Mei-Chuan Ko; James H Woods; William E Fantegrossi; Chad M Galuska; Jürgen Wichmann; Eric P Prinssen
Journal:  Neuropsychopharmacology       Date:  2009-03-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.